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SUMMARY
Background
There is uncertainty about how to measure patient-reported outcomes
(PROs) in IBS. The Food and Drug Administration (FDA) emphasizes that
PROs must be couched in a conceptual framework, yet existing IBS PROs
were not based on such a framework.
Aim
To perform qualitative analyses to inform a new conceptual framework for
IBS symptoms.
Methods
Following FDA guidance, we searched the literature for extant IBS ques-
tionnaires. We then performed interviews in IBS patients to learn about the
illness experience in their own words. We cultivated vocabulary to inform a
conceptual framework depicted with domains, sub-domains, and item cate-
gories, per FDA guidance.
Results
We identified 13 questionnaires with items encompassing 18 symptoms.
We recruited 123 IBS patients for cognitive interviews. Major themes
included: pain and discomfort are different – asking about discomfort is
nonspecific and should be avoided in future PROs; bowel urgency is multi-
faceted – PROs should measure bowel immediacy, controllability, and pre-
dictability; and PROs should divide bloating into how it feels vs. how it
looks. Symptom experience may be determined by 35-item categories
within five domains: (i) pain; (ii) gas ⁄ bloat; (iii) diarrhoea; (iv) constipation;
and (v) extraintestinal symptoms.
Conclusions
We applied FDA guidance to develop a framework that can serve as the
foundation for developing a PRO for IBS clinical trials.
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INTRODUCTION
Irritable Bowel Syndrome (IBS) is a multi-symptom con-
dition defined by abdominal pain, abdominal discomfort,
and abnormalities in stool frequency and form.1 IBS
remains a symptom-based condition that cannot yet be
reliably diagnosed or monitored with biomarkers alone;
patient report is essential to determine the diagnosis,
gauge overall disease severity, develop rational treatment
plans and assess outcomes.
Yet, there remains uncertainty about how best to
measure patient-reported outcomes (PROs) in IBS. This
challenge is at the centre stage for clinicians, investiga-
tors, and regulatory agencies such as the United States
Food and Drug Administration (FDA). The Rome
Foundation conducted an Endpoints and Outcomes
Conference in 2009 to help chart a course for optimiz-
ing PRO development in IBS and other functional
gastrointestinal disorders. The conference proceedings,
recently summarized by Chang and Drossman,2 high-
light the importance of developing a PRO that is reli-
able and valid. An optimal PRO must also be easily
administered, able to discriminate between illness sever-
ity states, predictable in behaviour when tracked with
other indicators of illness severity and readily interpret-
able.3 Without a valid and reliable PRO, it is not possi-
ble to test adequately the efficacy of existing and novel
compounds.
In its PRO guidance document, the FDA emphasizes
that an acceptable PRO must be couched in an explicit
and evidence-based conceptual framework.4 A PRO lack-
ing an underlying framework is not acceptable for use in
supporting label claims. Even if a PRO demonstrates reli-
ability and validity in psychometric testing, it remains
incomplete if there is no framework supporting its struc-
ture. Although there are many PROs in IBS,5 few were
developed based on an explicit conceptual framework,6
and none was derived from a framework built with all
the tools outlined in the explicit FDA guidance. In a
recent position statement published by the FDA Study
Endpoints and Label Development (SEALD) team and
the Division of Gastroenterology Products,6 Trentacosti
and colleagues emphasize that existing IBS PROs are
sub-optimal, and further indicate that several PRO topics
remain unresolved: (i) what patients mean by bowel
‘urgency’; (ii) whether there is a difference between
abdominal ‘pain’ and ‘discomfort’ – an important dis-
tinction as the current Rome III IBS diagnostic criteria
combine these terms;1 and (iii) what recall period is
acceptable for a questionnaire to capture accurately the
frequent dynamic symptom experience of IBS.
In light of the disconnect between FDA guidance and
the level of evidence supporting existing PROs, we must
delineate a clear conceptual framework for IBS symp-
toms; this is an essential first step towards creating and
validating a PRO for IBS clinical trials. This study pro-
vides the basis for a new conceptual framework. We
present mixed-methods data from 123 patients with IBS
that serve as foundation for this framework, including
data regarding the patient perception of bowel urgency,
the difference between pain vs. discomfort, and beliefs
about what recall period is appropriate across a range of
cardinal symptoms. We believe that these results can
serve as the foundation for future PRO development.
METHODS
Study overview
To develop a valid and reliable PRO for IBS, it is first nec-
essary to develop and justify an explicit conceptual frame-
work. According to the FDA PRO guidance, an adequate
conceptual framework defines the concepts measured by
the PRO.4 The framework must be rendered as a diagram
that portrays the hypothesized relationships between item
categories, sub-domains, domains and concepts that a
future PRO will ultimately intend to measure. For exam-
ple, a concept in IBS is the ‘IBS physical symptom experi-
ence’ (see Measurement concept, below). This concept
may comprise symptom domains, such as pain, diarrhoea,
constipation, or extraintestinal symptoms, among others.
These symptom domains, in turn, may have sub-domains;
for example, ‘urgency’ might be a sub-domain of diar-
rhoea. And sub-domains may comprise more granular
item categories; for example, ‘controllability’ or ‘predict-
ability’ might be item categories of urgency. Item catego-
ries are ultimately converted to scripted items that will
appear in a future PRO; for example, the item category of
‘urgency controllability’ might yield a specific item like:
‘How well did you control your bowel urgency today?’,
where options might range from ‘without any difficulty’
to ‘unable to control’.
In light of these distinctions, it is clear that a properly
developed framework provides structure for investigators
to create a PRO; without the conceptual framework, the
PRO developmental process can become random or dis-
organized. Although the framework may be later updated
or changed based on empirical testing, the initial frame-
work should nonetheless be constructed based on the
best available information.
As outlined by both the FDA4 and the NIH Patient
Reported Outcome Measurement Information System
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(PROMIS) Consortium,7, 8 multiple steps are necessary
to inform the construction of a conceptual framework.
First, investigators should conduct a literature review to
identify extant questionnaires and scripted items that
may relate to the concept of interest. Second, the result-
ing items should be reviewed and by experts with clinical
knowledge of the disease in question; these experts then
identify additional item categories that are not repre-
sented by the existing items from published question-
naires. Third, the expanded list of candidate item
categories should be sorted into an initial structure based
on qualitative review by experts. Fourth, investigators
must obtain open-ended, qualitative information from
patients with the target condition. These patients should
have a range of symptom expressions and be demo-
graphically diverse. The evaluations must seek informa-
tion about the patient experience of their illness in their
own words, including a description of the cardinal symp-
toms, the dimensions of those symptoms (e.g. frequency,
severity, bothersomeness, predictability, duration, etc.),
and the recall period that best captures those symptoms.
The patient elicitations must follow a structured script
designed to elicit open-ended feedback. Fifth, investiga-
tors must review and categorize the patient feedback to
cultivate patient vocabulary and inform the conceptual
framework. The sections below outline how we addressed
and achieved each of these FDA and PROMIS-recom-
mended steps in developing our IBS symptom conceptual
framework.
Measurement concept
The measurement concept of interest for our framework
is the IBS physical symptom experience. We focused on
physical symptoms because these are generally the pri-
mary outcome in IBS clinical trials.2, 5, 9 This is in con-
trast to other important symptoms and concepts,
including IBS emotional symptoms, IBS cognitions, IBS
health-related quality of life, and IBS work productivity.
The term ‘Symptom experience’ emphasizes that patients
experience their underlying disease in many different
ways, and those experiences may, or may not, mirror the
physiological severity of the disease.10, 11 An IBS PRO is
designed to measure the patients’ symptom experience,
first and foremost; this may ultimately correlate with
objective markers of disease, but that can only be deter-
mined in time. Therefore, we sought information regard-
ing the intestinal and extraintestinal physical symptom
experience in IBS, as manifested by individual physical
symptoms and their dimensions. This is in contrast to
the downstream psychosocial or functional impact of
these symptoms, as captured by questionnaires such as
the IBS-QOL,12 Visceral Sensitivity Index13 and IBS
Work Productivity Activity Index,14 among other ques-
tionnaires commonly used in IBS clinical research.15
Literature search strategy and expert review
We searched PubMed using a structured strategy devel-
oped in concert with an expert biomedical librarian. The
strategy employed validated search strings for PRO
instruments, as developed by PROMIS investigators at
the University of Pittsburgh.16 Appendix S1 provides the
details of our search strategy. This yielded previously
developed PROs in IBS, from which we extracted a list
of intestinal and extraintestinal symptoms. We then
compiled these symptoms and presented them to a panel
of six IBS experts (L.C., W.C., L.H., A.L., S.L., B.S.) who
evaluated the comprehensiveness of the list, added addi-
tional symptoms that were missing and helped to
develop bins to group symptoms based on the degree to
which they measured a similar concept. The main pur-
pose of binning, as outlined by PROMIS, is to identify
item categories and to create a taxonomy linking each
item category to the conceptual framework.17 The next
step was to reduce the number of item categories in dif-
ferent bins, also known as winnowing. We deleted (win-
nowed) item categories from within a bin in accordance
with the two PROMIS criteria for elimination: (i) lack of
face validity; or (ii) redundancy.17 The purpose of win-
nowing was to eliminate inferior item categories rather
than to select the best item categories. We applied the
PROMIS criteria for redundancy, including semantic
redundancy (i.e. item categories are identical or
nearly identical) and availability of a superior alternative
(i.e. another item category from the same bin is supe-
rior). We also applied the PROMIS criteria for rejecting
items due to face validity concerns, including inconsis-
tency with the domain definition, vagueness, and confus-
ing or misleading vocabulary. We also winnowed items
that were only rarely endorsed (i.e. by only 1 or
2 patients), or that did not appear related to IBS in
particular.
Obtaining patient input
We conducted two types of patient elicitations: (i) inten-
sive semi-structured individual cognitive interviews of a
cohort of 15 diverse IBS patients, and (ii) online ‘virtual
cognitive interviews’ of 108 IBS patients including both
open-ended qualitative probes and close-ended data col-
lection. The UCLA Institutional Review Board approved
all patient elicitations.
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Individual cognitive interviews. We recruited patients
who had been diagnosed with Rome III positive IBS1 by
a gastroenterologist at one of the following locations:
Atlanta Gastroenterology Associates, University of
California at Los Angeles, and Washington University.
We excluded patients if they had alarming signs or
symptoms or evidence of a competing organic aetiology
for IBS.18 To enhance generalizability of our sample, we
sought a range of patients across demographics, symp-
tom severity profiles, and IBS sub-types.
To create a structure for the cognitive interviews, we
conducted whiteboard exercises to delineate attributes of
the interviews based on the findings from our systematic
review. This resulted in a structured cognitive script
designed for a 45-min interview. We designed the inter-
views to be flexible so that new information and ideas
could be positioned within the evolving conceptual model.
Each interview began with an open-ended probe
employing the ‘think aloud’ technique of cognitive inter-
viewing.19 For example, we instructed patients to ‘please
tell us what comes to the top of your mind when you
think about your IBS symptoms’. Similarly, we explained
that ‘patients with IBS often experience many different
symptoms and describe them in many different ways’.
We followed this by instructing the patient to ‘list for us,
in your own words, each of the most important symp-
toms that come to mind’.
The interviewer then focused the respondent with a ser-
ies of directed scripted probes.19, 20 This technique allowed
the interviewer to explore the basis of a response, and to
apply the structure of the interview to the open-ended for-
mat. For example, if patients used the term ‘urgency’ to
describe their bowel movements, we then asked: ‘What
does ‘‘urgency’’ mean to you?’ We further sought informa-
tion about the dimensions of individual symptoms. For
example, if a patient reported abdominal pain as an
important symptom, we then evaluated whether it was the
intensity, frequency, duration, predictability, bothersome-
ness, or impact of the pain (or combination thereof) that
led them to choose pain as an important symptom.
Refer to Appendix S2 for the full script, including
introductory comments, think aloud instructions, and
scripted probes. The interviews were audiotaped and
transcribed for subsequent qualitative analysis. The
research team then reviewed the dialogue and abstracted
each report onto a semi-structured form that included
open fields to comment on dominant trends. This
qualitative process identified domains, sub-domains, and
individual item categories regarding IBS physical symp-
toms and their dimensions.
Online ‘virtual cognitive interviews’. Whereas individual
cognitive interviews provide a rich portrait of the patient
illness experience, they are limited because of their inher-
ently small sample size. We expanded our patient out-
reach to a larger sample using ‘virtual cognitive
interviews’ – a technique we have employed in previous
PRO research.21 This approach also helps to ensure that
saturation is reached – i.e. enough patients are inter-
viewed so that no new relevant or important information
emerges, and that additional patient elicitations are unli-
kely to provide incremental understanding about the ill-
ness experience.4 For these elicitations, we prospectively
recruited patients from the IBS Patient Reported
Observed Outcomes and Function (PROOF) cohort. An
overview of the PROOF cohort can be found in previous
publications.22, 23 PROOF is an internet-based, longitudi-
nal, observational registry of IBS patients identified
within a network of eight geographically diverse U.S.
centres, including both University-based and commu-
nity-based practices.
Patients in PROOF received an email with a link to
an online cognitive interview site. The site included the
same think aloud and scripted probes as the individual
cognitive interviews. Patients entered open-ended
responses into essay boxes, as demonstrated in Figure 1.
Following the open-ended section of the online inter-
view, we asked patients to select their most bothersome
symptom(s) among a list of symptoms established from
our review of extant items. Patients selecting individual
symptoms were then asked to explain, in their own
words, what the symptom means to them. In response to
FDA concerns,6 we specifically asked about how patients
define bowel urgency. We also focused on patient defini-
tions of other incompletely understood symptoms,
including constipation and bloating. As it remains
unclear whether patients distinguish abdominal pain vs.
discomfort, we also elicited patients’ understanding of
the difference. Finally, we asked patients to provide input
regarding an optimal recall period for various cardinal
IBS symptoms. Refer to https://www.surveymonkey.com/
s/5Q2SRGF for the full online cognitive interview and
related instructions.
Language cultivation and construction of a priori scales
We compiled the results into a written report and analy-
sed the data to cultivate and categorize language used by
patients to describe their symptom experience, and to
identify domains and items of relevance to patients. We
cross-matched this list with the item categories from the
literature search and expert input, and added new item
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categories to the growing list of candidate items for the
evolving framework. We then created a matrix that
categorized symptoms within conceptual categories, and
further categorized them by symptom dimensions identi-
fied by patients as important, including the frequency
(i.e. how often?), intensity (i.e. how bad?), bothersome-
ness, predictability, and impact (i.e. how much does it
interfere with daily activities?) of each symptom. Selec-
tion of relevant dimensions was guided by an evaluation
of qualitative feedback from cognitive interviews. Finally,
based on a priori hypotheses, the literature review, expert
panel input, and patient input, we developed a concep-
tual framework using the format required by the FDA
PRO guidance.4
RESULTS
Literature search strategy and expert review
Our search strategy identified more than 50 previously
developed PROs designed for IBS or other functional GI
disorders. Of these, we identified 13 that contain items
pertaining to IBS-related physical symptoms.24–33 We
developed an initial list of symptoms based on a review
of these PROs. Table 1 presents the list of PROs contain-
ing IBS symptoms along with 18 symptoms abstracted
from the instruments.
Patient cognitive interviews
We recruited 123 patients for cognitive interviews – 15
for intensive one-on-one interviews, and 108 for online
elicitations. Table 2 provides characteristics of the sam-
ples. The population spanned various demographic char-
acteristics, including race, education and income.
Eighteen percent of the cohort had IBS-C, 29% IBS-D
and 53% IBS-M using Rome III sub-classification crite-
ria.1 Using IBS-SSS criteria for symptom severity,25 17%,
46% and 37% of patients in the online group had mild,
moderate and severe IBS symptoms respectively. The full
open-ended feedback from the online elicitations is avail-
able at the following site: http://vfg.ResearchCORE.org.
The 108 online interviews yielded 49 symptoms, and the
15 one-on-one interviews elicited 24 symptoms (Appen-
dix S3). The sections below summarize major themes
that emerged from the interviews.
Symptom endorsement. Figure 2 presents the symptoms
most commonly endorsed by patients in open-ended
questioning. When asked to ‘list each of the most impor-
tant symptoms that come to mind’ patients across all
sub-types most commonly cited abdominal pain, bloating
and its variants, and flatulence ⁄ passing gas. Regarding
defecatory symptoms, IBS-C patients frequently reported
constipation (66%) in top-of-mind responses for the
Panel A
Panel B
Figure 1 | Sample screenshots from online cognitive
interview. Panel A demonstrates the introductory page
in which patients were instructed to provide top-of-
mind thoughts about IBS symptoms. Panel B demon-
strates the instructions for cultivating patient-reported
vocabulary about top-of-mind symptoms. Subsequent
screens elicited open-ended symptom descriptions.
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most important symptom, and less frequently reported
the specific constipation symptoms of straining (17%),
hard stools (11%), or incomplete evacuation (6%) as
most important. IBS-D patients reported diarrhoea
(60%) and urgency (33%) as most important symptoms,
and endorsed frequent stools (18%), loose stools (11%),









Age in years (mean  s.d.) 45  14 42  14








% Graduated high school 34% 78%
% Graduated college 33% 65%
% Postgraduate education 33% 27%
Income
% <$50 000 annual 29% 48%
% $50 000 to $100 000 annual 28% 30%
% >$100 000 annual 43% 22%
Employment status (% employed) 67% 66%
Marital status (% married) 67% 59%
IBS subtype
IBS with constipation (IBS-C) 33% 18%
IBS with diarrhoea (IBS-D) 47% 29%
Mixed IBS (IBS-M) 13% 53%
Unsubtyped IBS (IBS-U) 7% 0%
IBS duration
% 6 months to 1 year 7% 4%
% 1–2 years 8% 8%
% 2–5 years 20% 20%
% 5–10 years 27% 24%
% 10–20 years 40% 28%
% More than 20 years 0% 14%
IBS pain severity (10-point numeric rating scale) 3.7  2.4 4.7  2.6
Global IBS severity (0–20 rating scale) 7.8  4.7 11.2  5
IBS-SSS trichotomized severity
% Mild (score of 75–175) 47% 19%
% Moderate (score of 175–300) 53% 44%
% Severe (>300) 0% 37%
Worker Productivity Activity Index (WPAI:IBS)
% Work week absent from IBS (absenteeism) 3.0% 36%
% Work week impaired from IBS (presenteeism) 31.0% 34.4%
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and faecal incontinence or soilage (11%) less commonly.
Fatigue was the most common IBS-related extraintestinal
symptom reported in top-of-mind responses (28% in
IBS-C, 15% in IBS-D and 9% in IBS-M).
Pain vs. discomfort. Eighty-eight percent of patients
reported that pain and discomfort are different; 9% said
that they were the same and the remainder were unsure.
When asked to explain the difference, patients exhibited
wide variations in their understanding. In qualitative
responses, 14% described pain vs. discomfort as extremes
on a shared sensory scale, 36% described them as differ-
ent symptom categories, and 50% described them in
terms of varying functional impact. Refer to Table 3 for
sample responses. Other than abdominal pain itself, none
of the other IBS intestinal symptoms evaluated was per-
ceived to be predominantly painful, rather >40% of sub-
jects reported each of the IBS symptoms as
predominantly uncomfortable, except for straining
(36%). Figure 3 presents the full set of data regarding
patient perceptions of pain vs. discomfort.
Definition of urgency. There were 38 D-IBS patients in
the cognitive interviews of whom 36 reported urgency
(mean age = 43; 79% F). In qualitative responses,
patients reported four hierarchically ordered character-
izations of urgency: (i) simple description of symptom
and ⁄ or sensory experience (e.g. ‘feeling like my gut is
going to explode’; ‘feeling that faeces is about to explode
out of my rectum’); (ii) emphasis on the immediacy of
symptom (e.g. ‘dropping everything and getting to the
bathroom immediately’; ‘suddenly have to go without
warning’); (iii) emphasis that immediacy impacts con-
trollability (e.g. ‘feeling like I can’t stop a bowel move-
ment from coming before I reach the bathroom’; ‘feeling
of ‘‘I can’t hold it’’’); and (iv) emphasis that immediacy
and controllability impact psychosocial functioning (e.g.
‘fear of not getting there in time’; ‘it means not travelling
or going out of the house’). Additional quotes for each
characterization level are provided in Table 4.
Definition of bloating. Patients generally classified bloat-
ing into two major categories: how bloating looks, and
how bloating feels. Patients described the look of bloating
as ‘swollen’, ‘full of air’, ‘looking fat’, ‘looking pregnant’,
‘puffy’, ‘rounded out’, and ‘extended out’. Although some
patients described the look of bloating as ‘distended’,
many patients did not know what the word distended
means, and suggested that the word sounded ‘overly clini-
cal’ or ‘medical, like something a doctor would say’.
Patients described the feeling of bloating as ‘a feeling of
tightness’, ‘feeling full of air’, ‘feeling pressure’, ‘feeling
gassy’, ‘feeling that I need to pass gas’, ‘fullness’, ‘heavi-






















































































































































Figure 2 | Symptom endorsement of IBS patients in open-ended interviews. Patients were asked to ‘list each of the
symptoms that come to mind when you think about your IBS’. The figure depicts the most commonly endorsed symp-
toms from open-ended responses stratified by IBS sub-type and categorized by symptom type (pain, discomfort, defe-
catory, extraintestinal). It is important to note that these symptoms were top-of-mind, open-ended responses, not
endorsement using a pre-populated checklist of cardinal symptoms. The two techniques are likely to yield different
results.
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described bloating both in terms of look and feel, most
patients selected either one or the other category.
Definition of constipation. Consistent with previous
work in constipation, patients described constipation
using a range of descriptors and sub-symptoms, includ-
ing: ‘hard stools’, ‘straining to evacuate’, ‘needing to
apply pressure in order to initiate any movement’,
‘straining on bowel movements’, ‘infrequent bowel move-
ments’, ‘inability to have a bowel movement’, ‘inability to
have a bowel movement without a laxative’, ‘unable to
evacuate’, and ‘incomplete bowel movements’.
Gender differences. As previous data reveal symptom
differences between men and women with IBS,34 we
stratified our data by gender (Figure 4). Consistent with
a previous meta-analysis from our group,34 in this study,
we found that abdominal pain and constipation were
endorsed more frequently in women than in men,
whereas diarrhoea and incontinence were more common
among men than among women. We did not perform
statistical testing on these observations as they emerged
from qualitative patient interviews and were not designed
for quantitative statistical assessment.
Recall periods. Figure 5 presents data on patient
perceptions for the optimal recall period by symptom.
Table 3 | Example patient descriptions of ‘pain’ vs.
‘discomfort’. Responses are categorized into three
qualitative groups, as described further in the text
Pain vs. discomfort: defined as extremes on a shared sensory
scale
Pain is more severe. Discomfort is milder.
Discomfort is a mild level of pain.
Discomfort is a slight amount of pain.
Discomfort is mild. Pain is more intense.
Discomfort is milder than pain.
Discomfort is when you’re uncomfortable. Pain is when you’re
in agony.
On a scale of 1 to 5, discomfort to me would be a 1, 2, or 3
while pain would be a 4 or 5.
Pain vs. discomfort: defined as different symptom
categories
‘Pain’ is like a knife twisting. Discomfort is a strong, dull ache
throughout my belly.
Belly pain is like sharp, jabbing pain while belly discomfort is
more overall aching and upset stomach.
Discomfort is a sense of feeling unwell, uncomfortable.
Pain hurts and you want it to be over to stop
immediately.
Discomfort is gassy and pain hurts.
Discomfort is just something doesn’t feel right and relaxed, as
it should, but you can still live your life. Pain is like one step
further from discomfort. It feels like a nagging sensation and
becomes very difficult to ignore.
Discomfort is a kind of tightness and tenseness in the
abdomen.
Discomfort is the pressure, bloating, heaviness, and abnormal
sense in the belly. Pain is more associated when 1 have gas,
it is more sharp and in one spot. The discomfort is all over
my belly and just a general feeling all over.
Discomfort to me is feeling undigested, bloated, full, heavy, all
at the same time. Very uncomfortable. Pain is more acute
and it hurts. Discomfort is uncomfortable and annoying,
but not painful.
I associate pain with cramping and intense shooting or long
pain pulses in the abdomen. Discomfort might mean early
onset of symptoms or active stomach.
Pain for me is a sharp pain in my lower abdominal area.
Discomfort for me is being gassy and bloated.
Pain for me is usually sharp and specific to a location,
or a very intense pressure over an area. Discomfort
is more dull and unspecific; it’s difficult to point out
where it ends and difficult to describe how exactly it
feels.
Pain hurts. Discomfort just feels like pressure.
Pain hurts... Discomfort is an uncomfortable feeling.
Pain is more shooting, overworked muscles that failed to
release any tension in the bowel. I describe discomfort as
bloating and feeling ‘heavy,’ but not painful.
Table 3 | (Continued)
Pain vs. discomfort: defined in terms of varying functional impact
Pain is harder to ignore and more debilitating. Discomfort is
more varied in its impact on me.
Discomfort can be bothersome; pain can keep one from daily
actions and routines.
Discomfort can be ignored but pain cannot.
Pain is when it’s almost debilitating and you can be sitting on
the toilet for hours and discomfort is when you can still
accomplish tasks, but with some small amount of pain.
Discomfort is bearable and does not stop my day. Pain can
often be so bad I am doubled over and will throw up.
Discomfort is something that you can work through and pain
stops you from doing anything at all.
Discomfort is tolerable and will pass while pain can be
intolerable and sometimes never passes.
Discomfort is unpleasant, but not truly painful. Pain full on
hurts and impacts my ability to perform normal tasks.
Discomfort is you are not comfortable but the discomfort is
tolerable. Pain hurts and is not tolerable. Like someone is
digging a knife in your gut.
Pain interrupts activities while discomfort you ignore to the
best of your ability.
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For most of the symptoms, ‡30% of patients believed
that the symptom must be assessed at least daily to
capture properly the dynamic shifts in the symptom
experience. Defecatory symptoms required less frequent
recall periods.
Language cultivation and development of a priori
scales
Figure 6 presents the conceptual framework that
emerged from the data. The framework posits an overall
construct of IBS Physical Symptom Experience that is
determined by five domains: (i) IBS pain; (ii) IBS gas ⁄
bloat; (iii) IBS diarrhoea; (iv) IBS constipation; and (v)
IBS extraintestinal symptoms. Each of these domains is
discussed further, below.
IBS pain. Irritable Bowel Syndrome pain is manifested
by the dimensions of abdominal pain. Most patients sta-
ted that their abdominal pain is multifaceted, and that
some pain dimensions drive illness severity more than
others. Specifically, patients indicated that the intensity,
frequency, bothersomeness and predictability (e.g. ability
to tell in advance when a pain episode would occur) all
contribute towards their IBS pain experience. This is
consistent with previous quantitative analyses of data
from our PROOF cohort.35 In addition, many patients
believed that the specific location of their pain is impor-
tant, and that involvement of more abdominal regions
was related to a worse overall pain experience.
Many patients endorsed ‘cramping’ as an important IBS
symptom; these patients consistently believed that cramp-
ing is a form of pain, not a stand-alone symptom unto
itself. On the basis of this feedback, we concluded that
cramping is a descriptor of pain that is subsumed within
the IBS Pain domain; a separate cramping domain does
not appear to be necessary. In addition to cramping, other
commonly employed pain descriptors included ‘aching’,
‘burning’, ‘throbbing’, ‘squeezing’, ‘stabbing’, ‘twisting’,
‘jabbing’, ‘spasm’, and ‘sharp’, among others.
IBS gas ⁄bloat. As previously noted, patients referred to
bloating in terms its look and feel. Patients also referred
to ‘flatulence’ as a related, but separate symptom that
indicated passing gas (in contrast to gas retention with
subsequent visible bloating). Flatulence was largely con-
sidered a discomfort symptom grouped within the bloat-
ing complex rather than as a defecatory symptom,
namely because flatulence most often occurs outside the
context of bowel movements. Our framework posits that
IBS Gas ⁄ Bloat consists of three sub-domains: (i) bloating
sensation (i.e. feeling pressure or fullness); (ii) bloating
appearance (i.e. belly swollen or larger than usual size);
(iii) flatulence (i.e. passing gas). These sub-domains com-
prise individual items capturing the symptom dimensions
deemed important by patients in our cognitive interviews.
IBS diarrhoea. Irritable Bowel Syndrome diarrhoea is
the first of two defecatory domains in our conceptual
framework. The IBS Diarrhoea domain comprises three
sub-domains: (i) bowel urgency (i.e. having to rush
to the bathroom); (ii) bowel incontinence (i.e. having
‘accidents’); and (iii) stool soilage ⁄ leakage. The frame-
work includes items capturing the frequency, form,
impact, controllability and predictability of urgency.
Although bowel incontinence is unusual in IBS, it was
reported by some patients in our cohort, typically using
the term ‘accidents’. Incontinence was uniformly consid-
ered to be on a higher level of psychosocial impact
compared with urgency alone; patients believed that
incontinence should be separated from urgency as a
stand-alone symptom. Finally, many patients described































Both painful and uncomfortable
Neither painful nor uncomfortable
Unsure
I Do not have this symptom
Figure 3 | Patient perceptions
of ‘pain’ vs. ‘discomfort’ in IBS.
Patients were provided a list of
cardinal IBS symptoms, and
were asked: When you experi-
ence each symptom, does it
generally feel ‘painful’, ‘uncom-
fortable’, both ‘painful’ and
‘uncomfortable’, or neither?.
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urgency or incontinence. These patients explained that
soilage in their underpants, for example, was a trouble-
some symptom that often occurs independent of incon-
tinence or urgency.
IBS constipation. Irritable Bowel Syndrome constipation
is the second defecatory domain. It includes items cap-
turing the cardinal sub-symptoms of incomplete evacua-
tion, straining, infrequent stools and hard stools. These
symptoms are all included in the Rome III diagnostic
battery for constipation,1 and were independently
Table 4 | Example patient descriptions of ‘urgency’.
Patients were asked: ‘What does ‘‘urgency’’ mean to
you?’ Responses are categorized into four levels, as
described in the text
Level 1: Description of bowel urgency and its sensory experience
Need to get out the stool that is associated with the pain,
once it’s evacuated the pain stops.
Diarrhoea.
Feeling like my gut is going to explode.
Feeling that faeces is about to explode out of my rectum.
Sweating and shaking.
Level 2: Emphasis on immediacy
Dropping everything and getting to the bathroom immediately.
Feeling like I have to get the bathroom right now.
Feeling like I need to use the restroom now and if I don’t use
it I will have an accident.
Have to use the bathroom immediately.
I suddenly have to go without warning and often can’t make it
to the bathroom in time.
Must go to bathroom immediately.
Needing to find a toilet within a short amount of time frame,
like within 1 min.
Rushing to the toilet all the time.
Feeling that I have to go all of a sudden, with no warning.
The immediate need to go to the bathroom.
The need to go immediately.
Running to find a bathroom.
Must run to the nearest clean toilet.
Pain for me is a sharp pain in my lower abdominal area.
Discomfort for me is being gassy and bloated.
Pain for me is usually sharp and specific to a location, or a
very intense pressure over an area. Discomfort is more dull
and unspecific; it’s difficult to point out where it ends and
difficult to describe how exactly it feels.
Pain hurts. Discomfort just feels like pressure.
Pain hurts... Discomfort is an uncomfortable feeling.
Pain is more shooting, overworked muscles that failed to
release any tension in the bowel. I describe discomfort as
bloating and feeling ‘heavy,’ but not painful.
Level 3: Immediacy impacts controllability
Accidents. I have had near accidents and have had accidents
because I could not get to the bathroom in time.
Feeling like I can’t stop a bowel movement from coming before
I reach the bathroom.
Feeling like I need to use the restroom now and if I don’t use it
I will have an accident. There have been several times where
I have had to stop before my destination to find a restroom.
Often can’t make it to the bathroom in time.
Table 4 | (Continued)
Feeling of ‘I can’t hold it’.
Short lead time to get to a toilet, no control.
That I have just moments to get to a toilet or I will have an
accident.
Need to go to the bathroom. Almost uncontrollable.
Level 4: Immediacy and controllability impact psychosocial
functioning
Fear of not getting there in time.
It means no travelling or just going out of the house.
It means the stress of having to know where a bathroom is at
every location. I have not made it before, which was quite
frankly, disturbing, and caused post traumatic stress for sure.
Sitting in traffic is sometimes a scary thing. Travel in general is
nerve racking.
Worry that I can’t reach the bathroom in time.
100
Women (n = 94)






























































































































Figure 4 | Symptom endorsement stratified by gender.
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endorsed by the patients in our cognitive interviews
without specific prompting.
IBS extraintestinal symptoms. In addition to GI symp-
toms, patients endorsed a range of common extraintestinal
symptoms attributable to IBS. The most frequently refer-
enced symptoms were the presence of ‘fatigue’, ‘tiredness’,
feeling ‘clammy’ or ‘sweaty’, ‘faintness’, and ‘dizziness’.
IBS-D patients, in particular, reported episodes of sweati-
ness during bouts of urgency, often followed by feeling
tired and, in some cases, having to take an unscheduled
nap. It is notable that these symptoms may occur in the
absence of IBS, yet patients were able to specifically attri-
bute these symptoms to their IBS in particular, as opposed
to other conditions or to life in general.
DISCUSSION
There are ongoing efforts to develop a valid and mean-
ingful PRO in IBS.2 Yet, to date, there are no PROs that
meet the guidance set forth by the FDA.6 In this study,
we have laid the groundwork for a future PRO by devel-
oping a conceptual framework for measuring IBS symp-
toms based on the systematic, patient-driven approach
required by the FDA and PROMIS. Our study has six
main results:
First, on the basis of a systematic review of existing
PROs, input from key opinion leaders and open-ended
feedback from over 123 IBS patients, we developed a
conceptual framework for IBS Physical Symptom Experi-
ence (Figure 5). The framework posits that the physical
symptom experience comprises two abdominal symptom
domains (IBS pain, IBS gas ⁄ bloat), two defecatory
domains (IBS diarrhoea, IBS constipation) and one IBS
extraintestinal symptom domain. Future PRO develop-
ment will evaluate whether this a priori structure is sup-
ported by empirical data.
Second, we found that patients perceive their IBS
symptoms to be multi-dimensional. This has implications
for PRO development. When developing a PRO, it is
often unclear whether to measure individual symptoms
in terms of frequency (i.e. how often?), intensity (i.e.
how bad or severe?), or impact (i.e. how much does it
interfere with daily functions?). Rather than arbitrarily
selecting a symptom dimension, it is preferable to deter-
mine the importance of each dimension using data from
patients themselves. Our framework outlines the dimen-
sions patients perceive to be important for each of the
cardinal IBS symptoms (Figure 5). For example, we
found that abdominal pain is multifaceted in IBS, and
that some pain dimensions may drive the illness experi-
ence more than others. To understand fully the impact
of IBS pain on the overall symptom experience, trialists
may need to measure various dimensions of pain includ-
ing intensity (e.g. using 0–10 point numeric rating scale22
to measure the lowest, highest and mean daily pain
levels), frequency, impact (e.g. ‘How much did your pain
impact your quality of life today?’), predictability (e.g.
‘How well can you tell in advance when you will have
pain?’), bothersomeness and location. This approach of
measuring several dimensions is consistent with guidance
in other chronic pain disorders that emphasize the
multi-dimensionality of pain.36, 37
Third, we found that patients do not believe that pain
and discomfort are the same. This is in contrast to both
the Rome diagnostic criteria and IBS PROs that combine
pain and discomfort within one symptom category.1 The
FDA recognizes that although clinical trials have employed
PROs that group pain and discomfort,5, 38 it remains
unclear if these terms are perceived by patients to be syn-
onymous or different. Understanding this distinction is
essential for valid measurement. We therefore elicited IBS























































































Figure 5 | Patient perceptions
of optimal recall period for
individual IBS symptoms.
Patients were asked: ‘If we
needed to understand what
was going on with your typical
[symptom X] over a 1-week
period, how often would we
need to ask you about this?’.
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(e.g. feeling pressure or fullness)
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Feeling drained or fatigued
Numbness or tingling
Hot or cold spells
Faintness or dizziness


















Figure 6 | Conceptual framework of IBS physical symptom experience. The framework proposes that the IBS physical
symptom experience is determined by five major domains: IBS pain, IBS gas ⁄bloat, IBS diarrhoea, IBS constipation and
IBS extraintestinal symptoms.
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that the symptoms are indeed perceived as different by
most (88%) patients. Furthermore, we found that discom-
fort encompasses a range of symptoms such as bloating,
gas, fullness, flatulence, sensation of incomplete evacuation
and urgency. When asked to explain the difference,
patients exhibited wide variations in their understanding.
In short, asking patients about discomfort alone is nonspe-
cific because it covers many symptoms and concepts.
Future iterations of IBS diagnostic criteria and PROs
should distinguish pain from discomfort and further delin-
eate individual discomfort symptoms rather than aggregat-
ing under the shared discomfort construct.
Fourth, we found that many IBS-D and IBS-M
patients spontaneously use the word ‘urgency’ to describe
their bowel habits; that is, the term is not merely a clini-
cal contrivance. However, all of the subjects had sought
health care for their symptoms and it is not known if
the term urgency was secondarily adopted by the patient
from the providers’ terminology. When asked to define
urgency, patients described four hierarchically related
scales: (i) symptom description stratified by urgency
attributes; (ii) immediacy; (iii) controllability; and (iv)
psychosocial impact. Moreover, we found that urgency is
multifaceted with some symptom attributes driving the
illness experience more than others; urgency is not a uni-
dimensional symptom.
Fifth, patients refer to bloating in terms of its look
and its feel. The look of bloating is described as ‘swollen’,
‘full of air’, and ‘looking fat’, among other terms. Of
note, the words distension and distended, which are
commonly employed in both clinical practice and clinical
trials, were not widely recognized by patients in our cog-
nitive interviews. The feeling of bloating was variably
described as ‘tightness’, ‘feeling full of air’, and ‘feeling
pressure’, among other terms. Future PROs should dis-
tinguish the look vs. feel of bloating, and should avoid
using the term distension as it is not widely employed by
patients despite its common use among clinicians.
Last, we found that many IBS patients believe that
symptoms must be measured at least daily in order to
capture the dynamic nature of their illness experience.
This is consistent with the recent FDA recommendation
that IBS PROs include daily symptom assessments.6
Although some symptoms might be measured less fre-
quently (e.g. constipation symptoms), others should prob-
ably be measured at least daily (e.g. pain). As the lowest
common denominator is daily measurements, future
PROs may need to be administered daily until empirical
data support less frequent administration. This could be
accomplished either by scheduled once-daily question-
naire administrations, or even by momentary assessments
at random times of day with a personal digital assistant
(PDA) or interactive voice response system (IVRS), as
has been recently evaluated by Weinland and colleagues
in patients with IBS.39, 40 Additional research will evalu-
ate the correlations between daily and weekly IBS symp-
tom assessments, as has been performed extensively by
Stone and colleagues for somatic pain.41, 42 It may be that
less frequent administration will also be adequate for
measuring many physical symptoms in IBS, but before
deviating from FDA guidance, we will need empirical
data to support alternative schedules. Certainly global
endpoints, such as HRQOL, daily functioning, or work
productivity, will not require daily administrations – but
the FDA guidance is not currently focused on these types
of endpoints as primary outcome measures.
Our qualitative analyses have several strengths. We
have attempted to follow the FDA PRO guidance4
explicitly, and have bolstered this with techniques sup-
ported by the PROMIS consortium.8, 17 We began with
a literature search using a validated PROMIS search
strategy16 and coupled with input from an expert panel.
We relied upon patients with demographic and illness
severity variations to maximize the generalizability of
our sample. We performed open-ended interviews for
cognitive interviews. And we bolstered our one-on-one
interviews with a larger sample of online elicitations
using ‘virtual cognitive interviews’21 – a process that
yielded extensive and detailed responses and helped to
achieve thematic saturation.
As with any qualitative effort, our study has impor-
tant limitations. Although our conceptual framework is
explicitly portrayed (Figure 5), its structure must be
verified through empirical testing – only time and data
will tell. In addition, we did not focus on a single IBS
sub-type, but instead included representation from mul-
tiple types of IBS, including IBS-D, IBS-C, and IBS-M.
However, all IBS groups share the pain, gas ⁄ bloat, and
extraintestinal symptom domains; they vary only in
terms of defecatory symptoms. We found that IBS
patients share more symptoms in common than not,
and that the pain and gas ⁄ bloat domains fall in the
centre of the Venn diagrams among symptom groups.
A future PRO must be flexible to capture variations in
defecatory symptoms among groups, but otherwise
should measure common symptoms among groups –
there is no strong need to develop independent PROs
for different subgroups as this would be contrary to
what we have observed in this research. Nonetheless,
although IBS sub-types share more symptoms in com-
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mon than not, there remain differences among sub-
types in terms of the physical, cognitive, and emotional
illness experiences of IBS. The PRO development
process may benefit from additional research targeting
differences in the patient report by sub-type.
Our framework may also be criticized for including
extraintestinal symptoms. Extraintestinal symptoms may
not be directly attributable to IBS itself, and may also be
difficult to impact with gut-directed therapies. However,
the FDA and PROMIS emphasize the importance of cap-
turing the illness experience without considering the
mechanism of action (MOA) of current or future thera-
pies – PRO development and MOA considerations must
be strictly separated. And although IBS is generally con-
ceived as a bowel disorder, as implied by its very name,
patients tell us that IBS goes beyond the bowels in its
symptom expression. This may ultimately have patho-
physiological implications, but we cannot address mecha-
nistic questions at all in this study. However, we can
address the IBS illness experience, and our patients indi-
cate that IBS symptoms go beyond the intestines. More-
over, patients believe that these extraintestinal symptoms
can be attributed to IBS itself, as opposed to other health
conditions or to life in general. Thus, it may be short-
sighted to remove the extraintestinal symptoms from an
IBS PRO summarily, especially if the rationale is conve-
nience rather than to reflect the patient experience. Ulti-
mately empirical testing will determine whether this
domain has a place in the framework.
In conclusion, we have applied mixed-methods quali-
tative techniques to develop a conceptual framework for
measuring the physical symptom experience in IBS. Our
model suggests that the symptom experience comprises
pain, gas ⁄ bloat, diarrhoea, constipation and extraintesti-
nal symptom domains. This framework can now be
applied to develop and initially validate a novel PRO for
use in future IBS clinical trials.
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